ID   EXT1_HUMAN              Reviewed;         746 AA.
AC   Q16394; B2R7V2; Q9BVI9;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   27-MAR-2002, sequence version 2.
DT   28-JUN-2023, entry version 216.
DE   RecName: Full=Exostosin-1;
DE            EC=2.4.1.224;
DE            EC=2.4.1.225;
DE   AltName: Full=Glucuronosyl-N-acetylglucosaminyl-proteoglycan/N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase;
DE   AltName: Full=Multiple exostoses protein 1;
DE   AltName: Full=Putative tumor suppressor protein EXT1;
GN   Name=EXT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=7550340; DOI=10.1038/ng1095-137;
RA   Ahn J., Luedecke H.-J., Lindow S., Horton W.A., Lee B., Wagner M.J.,
RA   Horsthemke B., Wells D.E.;
RT   "Cloning of the putative tumour suppressor gene for hereditary multiple
RT   exostoses (EXT1).";
RL   Nat. Genet. 11:137-143(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-320.
RC   TISSUE=Lung;
RX   PubMed=9119404; DOI=10.1006/geno.1996.4577;
RA   Luedecke H.-J., Ahn J., Lin X., Hill A., Wagner M.J., Schomburg L.,
RA   Horsthemke B., Wells D.E.;
RT   "Genomic organization and promoter structure of the human EXT1 gene.";
RL   Genomics 40:351-354(1997).
RN   [6]
RP   SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=10679296; DOI=10.1006/bbrc.2000.2219;
RA   Kobayashi S., Morimoto K., Shimizu T., Takahashi M., Kurosawa H.,
RA   Shirasawa T.;
RT   "Association of EXT1 and EXT2, hereditary multiple exostoses gene products,
RT   in Golgi apparatus.";
RL   Biochem. Biophys. Res. Commun. 268:860-867(2000).
RN   [7]
RP   FUNCTION.
RX   PubMed=11518722; DOI=10.1172/jci13737;
RA   Duncan G., McCormick C., Tufaro F.;
RT   "The link between heparan sulfate and hereditary bone disease: finding a
RT   function for the EXT family of putative tumor suppressor proteins.";
RL   J. Clin. Invest. 108:511-516(2001).
RN   [8]
RP   FUNCTION.
RX   PubMed=22660413; DOI=10.1038/ncb2502;
RA   Baietti M.F., Zhang Z., Mortier E., Melchior A., Degeest G., Geeraerts A.,
RA   Ivarsson Y., Depoortere F., Coomans C., Vermeiren E., Zimmermann P.,
RA   David G.;
RT   "Syndecan-syntenin-ALIX regulates the biogenesis of exosomes.";
RL   Nat. Cell Biol. 14:677-685(2012).
RN   [9]
RP   INTERACTION WITH NDST1, AND SUBCELLULAR LOCATION.
RX   PubMed=35137078; DOI=10.1093/glycob/cwac004;
RA   Missaghian P., Dierker T., Khosrowabadi E., Axling F., Eriksson I.,
RA   Ghanem A., Kusche-Gullberg M., Kellokumpu S., Kjellen L.;
RT   "A dominant negative splice variant of the heparan sulfate biosynthesis
RT   enzyme NDST1 reduces heparan sulfate sulfation.";
RL   Glycobiology 0:0-0(2022).
RN   [10]
RP   REVIEW ON VARIANTS.
RX   PubMed=10679937;
RX   DOI=10.1002/(sici)1098-1004(200003)15:3<220::aid-humu2>3.0.co;2-k;
RA   Wuyts W., Van Hul W.;
RT   "Molecular basis of multiple exostoses: mutations in the EXT1 and EXT2
RT   genes.";
RL   Hum. Mutat. 15:220-227(2000).
RN   [11]
RP   VARIANTS EXT1 GLY-280 AND HIS-340.
RA   Raskind W.H., Matsushita M., Conrad E.U. III, Wells D.E., Sandell L.J.,
RA   Wagner M.J., Houck J.;
RT   "Spectrum of EXT1 mutations in hereditary multiple exostoses.";
RL   Am. J. Hum. Genet. 59:A280-A280(1996).
RN   [12]
RP   VARIANT EXT1 LEU-340.
RX   PubMed=8981950;
RA   Hecht J.T., Hogue D.A., Wang Y., Blanton S.H., Wagner M.J., Strong L.C.,
RA   Raskind W.H., Hansen M.F., Wells D.E.;
RT   "Hereditary multiple exostoses (EXT): mutational studies of familial EXT1
RT   cases and EXT-associated malignancies.";
RL   Am. J. Hum. Genet. 60:80-86(1997).
RN   [13]
RP   VARIANTS EXT1 ASP-339 AND CYS-340.
RX   PubMed=9326317; DOI=10.1086/515505;
RA   Philippe C., Porter D.E., Emerton M.E., Wells D.E., Simpson A.H.R.W.,
RA   Monaco A.P.;
RT   "Mutation screening of the EXT1 and EXT2 genes in patients with hereditary
RT   multiple exostoses.";
RL   Am. J. Hum. Genet. 61:520-528(1997).
RN   [14]
RP   VARIANTS EXT1 GLY-280 AND SER-340.
RX   PubMed=9463333; DOI=10.1086/301726;
RA   Wuyts W., van Hul W., de Boulle K., Hendrickx J., Bakker E.,
RA   Vanhoenacker F., Mollica F., Luedecke H.-J., Sayli B.S., Pazzaglia U.E.,
RA   Mortier G., Hamel B.C.J., Conrad E.U. III, Matsushita M., Raskind W.H.,
RA   Willems P.J.;
RT   "Mutations in the EXT1 and EXT2 genes in hereditary multiple exostoses.";
RL   Am. J. Hum. Genet. 62:346-354(1998).
RN   [15]
RP   VARIANTS EXT1 GLY-280; SER-280; HIS-340 AND HIS-627 DEL.
RX   PubMed=9521425;
RX   DOI=10.1002/(sici)1098-1004(1998)11:3<231::aid-humu8>3.0.co;2-k;
RA   Raskind W.H., Conrad E.U. III, Matsushita M., Wijsman E.M., Wells D.E.,
RA   Chapman N., Sandell L.J., Wagner M.J., Houck J.;
RT   "Evaluation of locus heterogeneity and EXT1 mutations in 34 families with
RT   hereditary multiple exostoses.";
RL   Hum. Mutat. 11:231-239(1998).
RN   [16]
RP   VARIANTS EXT1 HIS-164; 235-PRO--LYS-239 DEL AND SER-316.
RX   PubMed=10441575; DOI=10.1086/302532;
RA   Bovee J.V.M.G., Cleton-Jansen A.-M., Wuyts W., Caethoven G.,
RA   Taminiau A.H.M., Bakker E., van Hul W., Cornelisse C.J., Hogendoorn P.C.W.;
RT   "EXT-mutation analysis and loss of heterozygosity in sporadic and
RT   hereditary osteochondromas and secondary chondrosarcomas.";
RL   Am. J. Hum. Genet. 65:689-698(1999).
RN   [17]
RP   VARIANTS EXT1 VAL-486 AND LEU-496.
RX   PubMed=10480354; DOI=10.1007/s004399900058;
RA   Xu L., Xia J., Jiang H., Zhou J., Li H., Wang D., Pan Q., Long Z., Fan C.,
RA   Deng H.-X.;
RT   "Mutation analysis of hereditary multiple exostoses in the Chinese.";
RL   Hum. Genet. 105:45-50(1999).
RN   [18]
RP   VARIANT EXT1 215-MET--SER-221 DEL, AND VARIANT OSTEOCHONDROMA
RP   215-MET--SER-222 DELINS ILE.
RX   PubMed=11169766;
RX   DOI=10.1002/1097-0169(200102)48:2<149::aid-cm1005>3.0.co;2-3;
RA   Bernard M.A., Hall C.E., Hogue D.A., Cole W.G., Scott A., Snuggs M.B.,
RA   Clines G.A., Luedecke H.-J., Lovett M., Van Winkle W.B., Hecht J.T.;
RT   "Diminished levels of the putative tumor suppressor proteins EXT1 and EXT2
RT   in exostosis chondrocytes.";
RL   Cell Motil. Cytoskeleton 48:149-162(2001).
RN   [19]
RP   CHARACTERIZATION OF VARIANTS, AND MUTAGENESIS OF GLN-27; ASP-164; ASN-316;
RP   ALA-486 AND PRO-496.
RX   PubMed=11391482; DOI=10.1086/321278;
RA   Cheung P.K., McCormick C., Crawford B.E., Esko J.D., Tufaro F., Duncan G.;
RT   "Etiological point mutations in the hereditary multiple exostoses gene
RT   EXT1: a functional analysis of heparan sulfate polymerase activity.";
RL   Am. J. Hum. Genet. 69:55-66(2001).
CC   -!- FUNCTION: Glycosyltransferase required for the biosynthesis of heparan-
CC       sulfate. The EXT1/EXT2 complex possesses substantially higher
CC       glycosyltransferase activity than EXT1 or EXT2 alone. Appears to be a
CC       tumor suppressor. Required for the exosomal release of SDCBP, CD63 and
CC       syndecan (PubMed:22660413). {ECO:0000269|PubMed:11518722,
CC       ECO:0000269|PubMed:22660413}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3-O-{[(1->4)-beta-D-GlcA-(1->4)-alpha-D-GlcNAc](n)-(1->4)-
CC         beta-D-GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Xyl}-L-
CC         seryl-[protein] + UDP-N-acetyl-alpha-D-glucosamine = 3-O-{alpha-D-
CC         GlcNAc-[(1->4)-beta-D-GlcA-(1->4)-alpha-D-GlcNAc](n)-(1->4)-beta-D-
CC         GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Xyl}-L-seryl-
CC         [protein] + H(+) + UDP; Xref=Rhea:RHEA:16213, Rhea:RHEA-COMP:12621,
CC         Rhea:RHEA-COMP:12623, ChEBI:CHEBI:15378, ChEBI:CHEBI:57705,
CC         ChEBI:CHEBI:58223, ChEBI:CHEBI:132415, ChEBI:CHEBI:132416;
CC         EC=2.4.1.224;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3-O-{alpha-D-GlcNAc-[(1->4)-beta-D-GlcA-(1->4)-alpha-D-
CC         GlcNAc](n)-(1->4)-beta-D-GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-
CC         (1->4)-beta-D-Xyl}-L-seryl-[protein] + UDP-alpha-D-glucuronate = 3-
CC         O-{[(1->4)-beta-D-GlcA-(1->4)-alpha-D-GlcNAc](n+1)-(1->4)-beta-D-
CC         GlcA-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Xyl}-L-seryl-
CC         [protein] + H(+) + UDP; Xref=Rhea:RHEA:20908, Rhea:RHEA-COMP:12623,
CC         Rhea:RHEA-COMP:14295, ChEBI:CHEBI:15378, ChEBI:CHEBI:58052,
CC         ChEBI:CHEBI:58223, ChEBI:CHEBI:132415, ChEBI:CHEBI:132416;
CC         EC=2.4.1.225;
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000250|UniProtKB:Q9ES89};
CC   -!- PATHWAY: Protein modification; protein glycosylation.
CC   -!- SUBUNIT: Forms a homo/heterooligomeric complex with EXT2. Interacts
CC       with NDST1. {ECO:0000269|PubMed:10679296, ECO:0000269|PubMed:35137078}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:10679296}; Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:10679296}. Golgi apparatus membrane
CC       {ECO:0000269|PubMed:10679296}; Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:10679296}. Golgi apparatus, cis-Golgi network
CC       membrane {ECO:0000269|PubMed:35137078}; Single-pass type II membrane
CC       protein {ECO:0000255}. Note=The EXT1/EXT2 complex is localized in the
CC       Golgi apparatus.
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- DISEASE: Hereditary multiple exostoses 1 (EXT1) [MIM:133700]: EXT is a
CC       genetically heterogeneous bone disorder caused by genes segregating on
CC       human chromosomes 8, 11, and 19 and designated EXT1, EXT2 and EXT3
CC       respectively. EXT is a dominantly inherited skeletal disorder primarily
CC       affecting endochondral bone during growth. The disease is characterized
CC       by formation of numerous cartilage-capped, benign bone tumors
CC       (osteocartilaginous exostoses or osteochondromas) that are often
CC       accompanied by skeletal deformities and short stature. In a small
CC       percentage of cases exostoses have exhibited malignant transformation
CC       resulting in an osteosarcoma or chondrosarcoma. Osteochondromas
CC       development can also occur as a sporadic event.
CC       {ECO:0000269|PubMed:10441575, ECO:0000269|PubMed:10480354,
CC       ECO:0000269|PubMed:11169766, ECO:0000269|PubMed:8981950,
CC       ECO:0000269|PubMed:9326317, ECO:0000269|PubMed:9463333,
CC       ECO:0000269|PubMed:9521425, ECO:0000269|Ref.11}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- DISEASE: Tricho-rhino-phalangeal syndrome 2 (TRPS2) [MIM:150230]: A
CC       syndrome that combines the clinical features of tricho-rhino-phalangeal
CC       syndrome type 1 and multiple exostoses type 1. Affected individuals
CC       manifest multiple dysmorphic facial features including large, laterally
CC       protruding ears, a bulbous nose, an elongated upper lip, as well as
CC       sparse scalp hair, winged scapulae, multiple cartilaginous exostoses,
CC       redundant skin, and intellectual disability. Note=The gene represented
CC       in this entry is involved in disease pathogenesis. A chromosomal
CC       aberration resulting in the loss of functional copies of TRPS1 and EXT1
CC       has been found in TRPS2 patients.
CC   -!- DISEASE: Chondrosarcoma (CHDSA) [MIM:215300]: A malignant neoplasm
CC       derived from cartilage cells. Chondrosarcomas range from slow-growing
CC       non-metastasizing lesions to highly aggressive metastasizing sarcomas.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the glycosyltransferase 47 family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/212/EXT1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; S79639; AAB62283.1; -; mRNA.
DR   EMBL; AK313129; BAG35949.1; -; mRNA.
DR   EMBL; CH471060; EAW91972.1; -; Genomic_DNA.
DR   EMBL; BC001174; AAH01174.1; -; mRNA.
DR   EMBL; U70539; AAC51154.1; -; Genomic_DNA.
DR   CCDS; CCDS6324.1; -.
DR   RefSeq; NP_000118.2; NM_000127.2.
DR   PDB; 7SCH; EM; 3.10 A; A=28-746.
DR   PDB; 7SCJ; EM; 3.40 A; A=28-746.
DR   PDB; 7SCK; EM; 2.80 A; A=28-746.
DR   PDB; 7UQX; EM; 3.30 A; A=28-746.
DR   PDB; 7UQY; EM; 3.00 A; A=28-746.
DR   PDB; 7ZAY; EM; 2.80 A; A=29-746.
DR   PDBsum; 7SCH; -.
DR   PDBsum; 7SCJ; -.
DR   PDBsum; 7SCK; -.
DR   PDBsum; 7UQX; -.
DR   PDBsum; 7UQY; -.
DR   PDBsum; 7ZAY; -.
DR   AlphaFoldDB; Q16394; -.
DR   SMR; Q16394; -.
DR   BioGRID; 108432; 61.
DR   CORUM; Q16394; -.
DR   IntAct; Q16394; 24.
DR   STRING; 9606.ENSP00000367446; -.
DR   CAZy; GT47; Glycosyltransferase Family 47.
DR   CAZy; GT64; Glycosyltransferase Family 64.
DR   GlyCosmos; Q16394; 2 sites, No reported glycans.
DR   GlyGen; Q16394; 2 sites.
DR   iPTMnet; Q16394; -.
DR   PhosphoSitePlus; Q16394; -.
DR   BioMuta; EXT1; -.
DR   DMDM; 20141422; -.
DR   EPD; Q16394; -.
DR   MassIVE; Q16394; -.
DR   MaxQB; Q16394; -.
DR   PaxDb; Q16394; -.
DR   PeptideAtlas; Q16394; -.
DR   ProteomicsDB; 60869; -.
DR   Antibodypedia; 26732; 260 antibodies from 30 providers.
DR   DNASU; 2131; -.
DR   Ensembl; ENST00000378204.7; ENSP00000367446.3; ENSG00000182197.13.
DR   GeneID; 2131; -.
DR   KEGG; hsa:2131; -.
DR   MANE-Select; ENST00000378204.7; ENSP00000367446.3; NM_000127.3; NP_000118.2.
DR   UCSC; uc003yok.3; human.
DR   AGR; HGNC:3512; -.
DR   CTD; 2131; -.
DR   DisGeNET; 2131; -.
DR   GeneCards; EXT1; -.
DR   GeneReviews; EXT1; -.
DR   HGNC; HGNC:3512; EXT1.
DR   HPA; ENSG00000182197; Low tissue specificity.
DR   MalaCards; EXT1; -.
DR   MIM; 133700; phenotype.
DR   MIM; 150230; phenotype.
DR   MIM; 215300; phenotype.
DR   MIM; 608177; gene.
DR   neXtProt; NX_Q16394; -.
DR   OpenTargets; ENSG00000182197; -.
DR   Orphanet; 55880; Chondrosarcoma.
DR   Orphanet; 321; Multiple osteochondromas.
DR   Orphanet; 502; Trichorhinophalangeal syndrome type 2.
DR   PharmGKB; PA27924; -.
DR   VEuPathDB; HostDB:ENSG00000182197; -.
DR   eggNOG; KOG1021; Eukaryota.
DR   GeneTree; ENSGT00940000155321; -.
DR   HOGENOM; CLU_013906_4_0_1; -.
DR   InParanoid; Q16394; -.
DR   OMA; YHRYYNT; -.
DR   OrthoDB; 1220028at2759; -.
DR   PhylomeDB; Q16394; -.
DR   TreeFam; TF314231; -.
DR   BioCyc; MetaCyc:HS00012-MON; -.
DR   BRENDA; 2.4.1.224; 2681.
DR   BRENDA; 2.4.1.225; 2681.
DR   PathwayCommons; Q16394; -.
DR   Reactome; R-HSA-2022928; HS-GAG biosynthesis.
DR   Reactome; R-HSA-3656237; Defective EXT2 causes exostoses 2.
DR   Reactome; R-HSA-3656253; Defective EXT1 causes exostoses 1, TRPS2 and CHDS.
DR   SignaLink; Q16394; -.
DR   SIGNOR; Q16394; -.
DR   UniPathway; UPA00378; -.
DR   BioGRID-ORCS; 2131; 88 hits in 1183 CRISPR screens.
DR   ChiTaRS; EXT1; human.
DR   GeneWiki; EXT1; -.
DR   GenomeRNAi; 2131; -.
DR   Pharos; Q16394; Tbio.
DR   PRO; PR:Q16394; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; Q16394; protein.
DR   Bgee; ENSG00000182197; Expressed in stromal cell of endometrium and 200 other tissues.
DR   ExpressionAtlas; Q16394; baseline and differential.
DR   Genevisible; Q16394; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:BHF-UCL.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; ISS:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:BHF-UCL.
DR   GO; GO:0000139; C:Golgi membrane; TAS:BHF-UCL.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0045202; C:synapse; IEA:GOC.
DR   GO; GO:0008375; F:acetylglucosaminyltransferase activity; IDA:BHF-UCL.
DR   GO; GO:0050508; F:glucuronosyl-N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase activity; ISS:UniProtKB.
DR   GO; GO:0015020; F:glucuronosyltransferase activity; IDA:BHF-UCL.
DR   GO; GO:0016757; F:glycosyltransferase activity; IDA:BHF-UCL.
DR   GO; GO:0042328; F:heparan sulfate N-acetylglucosaminyltransferase activity; NAS:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0050509; F:N-acetylglucosaminyl-proteoglycan 4-beta-glucuronosyltransferase activity; ISS:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0019882; P:antigen processing and presentation; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0071711; P:basement membrane organization; IEA:Ensembl.
DR   GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl.
DR   GO; GO:0030509; P:BMP signaling pathway; IEA:Ensembl.
DR   GO; GO:0045453; P:bone resorption; IEA:Ensembl.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0060351; P:cartilage development involved in endochondral bone morphogenesis; IEA:Ensembl.
DR   GO; GO:0033627; P:cell adhesion mediated by integrin; IEA:Ensembl.
DR   GO; GO:0045165; P:cell fate commitment; IEA:Ensembl.
DR   GO; GO:0098586; P:cellular response to virus; IEA:Ensembl.
DR   GO; GO:0003415; P:chondrocyte hypertrophy; IEA:Ensembl.
DR   GO; GO:0035988; P:chondrocyte proliferation; IEA:Ensembl.
DR   GO; GO:0030204; P:chondroitin sulfate metabolic process; IEA:Ensembl.
DR   GO; GO:0030199; P:collagen fibril organization; IEA:Ensembl.
DR   GO; GO:1904888; P:cranial skeletal system development; IEA:Ensembl.
DR   GO; GO:0070593; P:dendrite self-avoidance; IEA:Ensembl.
DR   GO; GO:0036336; P:dendritic cell migration; IEA:Ensembl.
DR   GO; GO:0060560; P:developmental growth involved in morphogenesis; IEA:Ensembl.
DR   GO; GO:0072498; P:embryonic skeletal joint development; IEA:Ensembl.
DR   GO; GO:0003416; P:endochondral bone growth; IEA:Ensembl.
DR   GO; GO:0001958; P:endochondral ossification; IEA:Ensembl.
DR   GO; GO:0007492; P:endoderm development; IEA:Ensembl.
DR   GO; GO:0060441; P:epithelial tube branching involved in lung morphogenesis; IEA:Ensembl.
DR   GO; GO:0042596; P:fear response; IEA:Ensembl.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0042044; P:fluid transport; IEA:Ensembl.
DR   GO; GO:0007369; P:gastrulation; IEA:Ensembl.
DR   GO; GO:0010467; P:gene expression; IEA:Ensembl.
DR   GO; GO:0002067; P:glandular epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0032836; P:glomerular basement membrane development; IEA:Ensembl.
DR   GO; GO:0006024; P:glycosaminoglycan biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IEA:Ensembl.
DR   GO; GO:0060047; P:heart contraction; IEA:Ensembl.
DR   GO; GO:0003128; P:heart field specification; IEA:Ensembl.
DR   GO; GO:0060218; P:hematopoietic stem cell differentiation; IEA:Ensembl.
DR   GO; GO:0061484; P:hematopoietic stem cell homeostasis; IEA:Ensembl.
DR   GO; GO:0097241; P:hematopoietic stem cell migration to bone marrow; IEA:Ensembl.
DR   GO; GO:0015012; P:heparan sulfate proteoglycan biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0015014; P:heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0030210; P:heparin biosynthetic process; IEA:Ensembl.
DR   GO; GO:0002524; P:hypersensitivity; IEA:Ensembl.
DR   GO; GO:0050901; P:leukocyte tethering or rolling; IEA:Ensembl.
DR   GO; GO:0036022; P:limb joint morphogenesis; IEA:Ensembl.
DR   GO; GO:0036339; P:lymphocyte adhesion to endothelial cell of high endothelial venule; IEA:Ensembl.
DR   GO; GO:0097021; P:lymphocyte migration into lymphoid organs; IEA:Ensembl.
DR   GO; GO:1901706; P:mesenchymal cell differentiation involved in bone development; IEA:Ensembl.
DR   GO; GO:0007498; P:mesoderm development; IEA:Ensembl.
DR   GO; GO:0061744; P:motor behavior; IEA:Ensembl.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0050891; P:multicellular organismal-level water homeostasis; IEA:Ensembl.
DR   GO; GO:0014033; P:neural crest cell differentiation; IEA:Ensembl.
DR   GO; GO:0021772; P:olfactory bulb development; IEA:Ensembl.
DR   GO; GO:0021554; P:optic nerve development; IEA:Ensembl.
DR   GO; GO:0001503; P:ossification; IMP:BHF-UCL.
DR   GO; GO:0043931; P:ossification involved in bone maturation; IEA:Ensembl.
DR   GO; GO:0061974; P:perichondral bone morphogenesis; IEA:Ensembl.
DR   GO; GO:0072112; P:podocyte differentiation; IEA:Ensembl.
DR   GO; GO:0000271; P:polysaccharide biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0030163; P:protein catabolic process; IEA:Ensembl.
DR   GO; GO:0006486; P:protein glycosylation; IEA:UniProtKB-UniPathway.
DR   GO; GO:0065003; P:protein-containing complex assembly; IEA:Ensembl.
DR   GO; GO:0008217; P:regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:0071503; P:response to heparin; IEA:Ensembl.
DR   GO; GO:1990823; P:response to leukemia inhibitory factor; IEA:Ensembl.
DR   GO; GO:0009642; P:response to light intensity; IEA:Ensembl.
DR   GO; GO:0048733; P:sebaceous gland development; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   GO; GO:0060506; P:smoothened signaling pathway involved in lung development; IEA:Ensembl.
DR   GO; GO:0035176; P:social behavior; IEA:Ensembl.
DR   GO; GO:0055078; P:sodium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0017145; P:stem cell division; IEA:Ensembl.
DR   GO; GO:0062094; P:stomach development; IEA:Ensembl.
DR   GO; GO:0051923; P:sulfation; IEA:Ensembl.
DR   GO; GO:0060792; P:sweat gland development; IEA:Ensembl.
DR   GO; GO:0035249; P:synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0120193; P:tight junction organization; IEA:Ensembl.
DR   GO; GO:0071847; P:TNFSF11-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0007033; P:vacuole organization; IEA:Ensembl.
DR   GO; GO:0042311; P:vasodilation; IEA:Ensembl.
DR   GO; GO:0071625; P:vocalization behavior; IEA:Ensembl.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   InterPro; IPR004263; Exostosin.
DR   InterPro; IPR040911; Exostosin_GT47.
DR   InterPro; IPR015338; GT64.
DR   InterPro; IPR029044; Nucleotide-diphossugar_trans.
DR   PANTHER; PTHR48261; ACETYLGLUCOSAMINYLTRANSFERASE; 1.
DR   PANTHER; PTHR48261:SF2; ACETYLGLUCOSAMINYLTRANSFERASE; 1.
DR   Pfam; PF03016; Exostosin; 1.
DR   Pfam; PF09258; Glyco_transf_64; 1.
DR   SUPFAM; SSF53448; Nucleotide-diphospho-sugar transferases; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Disease variant; Disulfide bond; Endoplasmic reticulum;
KW   Glycoprotein; Glycosyltransferase; Golgi apparatus;
KW   Hereditary multiple exostoses; Manganese; Membrane; Metal-binding;
KW   Reference proteome; Signal-anchor; Transferase; Transmembrane;
KW   Transmembrane helix; Tumor suppressor.
FT   CHAIN           1..746
FT                   /note="Exostosin-1"
FT                   /id="PRO_0000149648"
FT   TOPO_DOM        1..7
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        8..28
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        29..746
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        654
FT                   /evidence="ECO:0000250|UniProtKB:Q9ES89"
FT   BINDING         440
FT                   /ligand="UDP-N-acetyl-alpha-D-glucosamine"
FT                   /ligand_id="ChEBI:CHEBI:57705"
FT                   /evidence="ECO:0000250|UniProtKB:Q9ES89"
FT   BINDING         549
FT                   /ligand="UDP-N-acetyl-alpha-D-glucosamine"
FT                   /ligand_id="ChEBI:CHEBI:57705"
FT                   /evidence="ECO:0000250|UniProtKB:Q9ES89"
FT   BINDING         565
FT                   /ligand="UDP-N-acetyl-alpha-D-glucosamine"
FT                   /ligand_id="ChEBI:CHEBI:57705"
FT                   /evidence="ECO:0000250|UniProtKB:Q9ES89"
FT   BINDING         566
FT                   /ligand="UDP-N-acetyl-alpha-D-glucosamine"
FT                   /ligand_id="ChEBI:CHEBI:57705"
FT                   /evidence="ECO:0000250|UniProtKB:Q9ES89"
FT   BINDING         567
FT                   /ligand="Mn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29035"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000250|UniProtKB:Q9ES89"
FT   BINDING         567
FT                   /ligand="UDP-N-acetyl-alpha-D-glucosamine"
FT                   /ligand_id="ChEBI:CHEBI:57705"
FT                   /evidence="ECO:0000250|UniProtKB:Q9ES89"
FT   BINDING         653
FT                   /ligand="UDP-N-acetyl-alpha-D-glucosamine"
FT                   /ligand_id="ChEBI:CHEBI:57705"
FT                   /evidence="ECO:0000250|UniProtKB:Q9ES89"
FT   BINDING         654
FT                   /ligand="UDP-N-acetyl-alpha-D-glucosamine"
FT                   /ligand_id="ChEBI:CHEBI:57705"
FT                   /evidence="ECO:0000250|UniProtKB:Q9ES89"
FT   BINDING         701
FT                   /ligand="UDP-N-acetyl-alpha-D-glucosamine"
FT                   /ligand_id="ChEBI:CHEBI:57705"
FT                   /evidence="ECO:0000250|UniProtKB:Q9ES89"
FT   CARBOHYD        89
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        330
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        652..704
FT                   /evidence="ECO:0000250|UniProtKB:Q9ES89"
FT   VARIANT         27
FT                   /note="Q -> K (in EXT1; no loss of activity)"
FT                   /id="VAR_012815"
FT   VARIANT         164
FT                   /note="D -> H (in EXT1; loss of activity)"
FT                   /evidence="ECO:0000269|PubMed:10441575"
FT                   /id="VAR_012816"
FT   VARIANT         215..222
FT                   /note="MLAKASIS -> I (in isolated osteochondroma; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:11169766"
FT                   /id="VAR_012818"
FT   VARIANT         215..221
FT                   /note="Missing (in EXT1)"
FT                   /id="VAR_012817"
FT   VARIANT         235..239
FT                   /note="Missing (in multiple osteochondromas)"
FT                   /evidence="ECO:0000269|PubMed:10441575"
FT                   /id="VAR_012819"
FT   VARIANT         280
FT                   /note="R -> G (in EXT1; loss of activity;
FT                   dbSNP:rs1554601483)"
FT                   /evidence="ECO:0000269|PubMed:9463333,
FT                   ECO:0000269|PubMed:9521425, ECO:0000269|Ref.11"
FT                   /id="VAR_002370"
FT   VARIANT         280
FT                   /note="R -> S (in EXT1; loss of activity;
FT                   dbSNP:rs1563659325)"
FT                   /evidence="ECO:0000269|PubMed:9521425"
FT                   /id="VAR_002371"
FT   VARIANT         316
FT                   /note="N -> S (in chondrosarcoma; no loss of activity)"
FT                   /evidence="ECO:0000269|PubMed:10441575"
FT                   /id="VAR_012820"
FT   VARIANT         339
FT                   /note="G -> D (in EXT1; loss of activity;
FT                   dbSNP:rs119103288)"
FT                   /evidence="ECO:0000269|PubMed:9326317"
FT                   /id="VAR_002372"
FT   VARIANT         340
FT                   /note="R -> C (in EXT1; loss of activity; still able to
FT                   form an oligomeric complex; dbSNP:rs119103290)"
FT                   /evidence="ECO:0000269|PubMed:9326317"
FT                   /id="VAR_002373"
FT   VARIANT         340
FT                   /note="R -> H (in EXT1; loss of activity;
FT                   dbSNP:rs119103287)"
FT                   /evidence="ECO:0000269|PubMed:9521425, ECO:0000269|Ref.11"
FT                   /id="VAR_002374"
FT   VARIANT         340
FT                   /note="R -> L (in EXT1; loss of activity;
FT                   dbSNP:rs119103287)"
FT                   /evidence="ECO:0000269|PubMed:8981950"
FT                   /id="VAR_002375"
FT   VARIANT         340
FT                   /note="R -> S (in EXT1; loss of activity)"
FT                   /evidence="ECO:0000269|PubMed:9463333"
FT                   /id="VAR_002376"
FT   VARIANT         486
FT                   /note="A -> V (in EXT1; no loss of activity;
FT                   dbSNP:rs188859975)"
FT                   /evidence="ECO:0000269|PubMed:10480354"
FT                   /id="VAR_012821"
FT   VARIANT         496
FT                   /note="P -> L (in EXT1; no loss of activity)"
FT                   /evidence="ECO:0000269|PubMed:10480354"
FT                   /id="VAR_012822"
FT   VARIANT         627
FT                   /note="Missing (in EXT1; loss of activity)"
FT                   /evidence="ECO:0000269|PubMed:9521425"
FT                   /id="VAR_002377"
FT   MUTAGEN         27
FT                   /note="Q->A,P: No effect on heparan-sulfate biosynthesis."
FT                   /evidence="ECO:0000269|PubMed:11391482"
FT   MUTAGEN         27
FT                   /note="Missing: No effect on heparan-sulfate biosynthesis."
FT                   /evidence="ECO:0000269|PubMed:11391482"
FT   MUTAGEN         164
FT                   /note="D->E: Abolishes heparan-sulfate biosynthesis."
FT                   /evidence="ECO:0000269|PubMed:11391482"
FT   MUTAGEN         164
FT                   /note="Missing: Abolishes heparan-sulfate biosynthesis."
FT                   /evidence="ECO:0000269|PubMed:11391482"
FT   MUTAGEN         316
FT                   /note="N->A: No effect on heparan-sulfate biosynthesis."
FT                   /evidence="ECO:0000269|PubMed:11391482"
FT   MUTAGEN         316
FT                   /note="Missing: No effect on heparan-sulfate biosynthesis."
FT                   /evidence="ECO:0000269|PubMed:11391482"
FT   MUTAGEN         486
FT                   /note="A->H: No effect on heparan-sulfate biosynthesis."
FT                   /evidence="ECO:0000269|PubMed:11391482"
FT   MUTAGEN         486
FT                   /note="Missing: No effect on heparan-sulfate biosynthesis."
FT                   /evidence="ECO:0000269|PubMed:11391482"
FT   MUTAGEN         496
FT                   /note="P->H: No effect on heparan-sulfate biosynthesis."
FT                   /evidence="ECO:0000269|PubMed:11391482"
FT   MUTAGEN         496
FT                   /note="Missing: No effect on heparan-sulfate biosynthesis."
FT                   /evidence="ECO:0000269|PubMed:11391482"
FT   CONFLICT        60..61
FT                   /note="DA -> EP (in Ref. 1 and 3)"
FT                   /evidence="ECO:0000305"
FT   HELIX           83..92
FT                   /evidence="ECO:0007829|PDB:7SCH"
FT   STRAND          94..97
FT                   /evidence="ECO:0007829|PDB:7UQX"
FT   TURN            100..102
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   HELIX           106..108
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   TURN            110..112
FT                   /evidence="ECO:0007829|PDB:7UQY"
FT   STRAND          116..118
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          123..125
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   HELIX           129..139
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          144..146
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   TURN            148..150
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          152..155
FT                   /evidence="ECO:0007829|PDB:7UQY"
FT   STRAND          161..163
FT                   /evidence="ECO:0007829|PDB:7SCJ"
FT   HELIX           175..179
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   TURN            185..187
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          188..194
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          200..202
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          215..220
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   HELIX           223..225
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   TURN            228..230
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          243..245
FT                   /evidence="ECO:0007829|PDB:7UQX"
FT   STRAND          261..269
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          272..276
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   TURN            278..282
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   HELIX           283..286
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          289..297
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   TURN            304..307
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   HELIX           310..319
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   HELIX           324..328
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          331..336
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          340..342
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   HELIX           346..352
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          356..359
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   TURN            367..371
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   TURN            374..377
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          378..380
FT                   /evidence="ECO:0007829|PDB:7SCH"
FT   HELIX           383..385
FT                   /evidence="ECO:0007829|PDB:7UQY"
FT   HELIX           389..394
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   HELIX           398..414
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          416..418
FT                   /evidence="ECO:0007829|PDB:7UQX"
FT   HELIX           419..431
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   TURN            432..434
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          436..438
FT                   /evidence="ECO:0007829|PDB:7UQX"
FT   HELIX           442..445
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          447..449
FT                   /evidence="ECO:0007829|PDB:7UQX"
FT   TURN            451..453
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   TURN            456..458
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   HELIX           462..464
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          465..467
FT                   /evidence="ECO:0007829|PDB:7SCJ"
FT   TURN            469..473
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          480..486
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   HELIX           496..505
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          510..517
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   HELIX           526..528
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          536..540
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   HELIX           546..550
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          558..565
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   HELIX           572..582
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          586..588
FT                   /evidence="ECO:0007829|PDB:7UQX"
FT   STRAND          590..592
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          594..600
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   TURN            601..604
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          605..609
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          616..619
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          623..627
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   HELIX           629..636
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   HELIX           640..649
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   HELIX           653..665
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          670..674
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   HELIX           696..712
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   STRAND          722..725
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   TURN            735..737
FT                   /evidence="ECO:0007829|PDB:7SCK"
FT   HELIX           741..743
FT                   /evidence="ECO:0007829|PDB:7SCK"
SQ   SEQUENCE   746 AA;  86255 MW;  842CD7E6C1312C1A CRC64;
     MQAKKRYFIL LSAGSCLALL FYFGGLQFRA SRSHSRREEH SGRNGLHHPS PDHFWPRFPD
     ALRPFVPWDQ LENEDSSVHI SPRQKRDANS SIYKGKKCRM ESCFDFTLCK KNGFKVYVYP
     QQKGEKIAES YQNILAAIEG SRFYTSDPSQ ACLFVLSLDT LDRDQLSPQY VHNLRSKVQS
     LHLWNNGRNH LIFNLYSGTW PDYTEDVGFD IGQAMLAKAS ISTENFRPNF DVSIPLFSKD
     HPRTGGERGF LKFNTIPPLR KYMLVFKGKR YLTGIGSDTR NALYHVHNGE DVVLLTTCKH
     GKDWQKHKDS RCDRDNTEYE KYDYREMLHN ATFCLVPRGR RLGSFRFLEA LQAACVPVML
     SNGWELPFSE VINWNQAAVI GDERLLLQIP STIRSIHQDK ILALRQQTQF LWEAYFSSVE
     KIVLTTLEII QDRIFKHISR NSLIWNKHPG GLFVLPQYSS YLGDFPYYYA NLGLKPPSKF
     TAVIHAVTPL VSQSQPVLKL LVAAAKSQYC AQIIVLWNCD KPLPAKHRWP ATAVPVVVIE
     GESKVMSSRF LPYDNIITDA VLSLDEDTVL STTEVDFAFT VWQSFPERIV GYPARSHFWD
     NSKERWGYTS KWTNDYSMVL TGAAIYHKYY HYLYSHYLPA SLKNMVDQLA NCEDILMNFL
     VSAVTKLPPI KVTQKKQYKE TMMGQTSRAS RWADPDHFAQ RQSCMNTFAS WFGYMPLIHS
     QMRLDPVLFK DQVSILRKKY RDIERL
//
